Challenger thrombolytic prevails in battle of the clot-busters

Australian trial could pave the way for a change in bridging therapy

A cheaper thrombolytic appears to double the chances of reperfusion in patients with ischaemic stroke prior to thrombectomy, compared with the standard drug, Australian research shows.